June 19, 2014
Pfizer Japan’s rheumatoid arthritis treatment Xeljanz (tofacitinib) is nearing the end of its first year on the market. In its six-month early post-marketing phase vigilance (EPPV), four episodes of serious adverse drug reactions (ADRs) including pneumonia and heart failure were...read more